DIANNA CLYNE: Open Payments
NPI 1114035938 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,345 in 128 payments from 16 companies in 2025. Trend: 2023 $2,827 · 2024 $6,580 · 2025 $2,345
Food & beverage: $2,345
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $570 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $339 |
| Otsuka America Pharmaceutical, Inc. | 20 | $299 |
| Alkermes, Inc. | 15 | $267 |
| Teva Pharmaceuticals USA, Inc. | 12 | $223 |
| Neurocrine BioSciences, Inc. | 6 | $121 |
| Axsome Therapeutics, Inc. | 6 | $108 |
| Lundbeck LLC | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
Products named: VRAYLAR, REXULTI, CAPLYTA, ARISTADA, UZEDY, INGREZZA, AUSTEDO XR, Auvelity.
Industry payments across NE — which companies pay providers there.
